Search Results

Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.

Vaccibody becomes Nykode Therapeutics — a new name and identity, including logo, colors and website, to signify a new phase of growth and development.

“We are very excited to have entered into this transformative agreement that marks the start of a new era for Vaccibody,” Michael Engsig, CEO of Vaccibody, said in a statement.

Vaccibody AS and Nektar Therapeutics announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin, Nektar’s CD122-preferential IL-2 pathway agonist, with VB10.NEO, Vaccibody’s personalized neoantigen cancer vaccine, in patients with advanced squamous cell carcinoma of the head and neck.

Nykode Therapeutics announced that it has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialization of potential new vaccines for cancer and infectious diseases.

Vaccibody AS and Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of new preclinical data for VB10.NEO, a personalized neoantigen cancer vaccine, combined with bempegaldesleukin (NKTR-214 or bempeg), a CD122-preferential IL-2 pathway agonist

Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced that preclinical data from its Vaccibody™ vaccine platform technology will be presented at the upcoming 2022 American Association for Cancer Research (AACR) Annual Meeting.

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants.

PharmaJet is expanding their human clinical trial for the study of a vaccine to treat HPV disease using the PharmaJet Stratis needle-free injection system.